A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Dec 2017 According to an Eisai media release, based on the results from this trial, Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China.
30 Sep 2014 Top-line results published in an Eisai media release. Based on the results of this trial, an application will be made to Chinese regulatory authorities to extend the indications for donepezil to include severe Alzheimer's disease.
30 Sep 2014 Primary endpoint has been met (Change in total Severe Impairment Battery score at Week 24; significant superiority of donepezil vs placebo), according to an Eisai media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com